Pharmacological Effects Spiriva Inhaler:
Spiriva Inhaler Bronchodilatory agent, blocks the M-cholinergic receptors of smooth muscle of the tracheobronchial tree. Has the same affinity for different subtypes of muscarinic receptors from M1 to M5. The result of inhibition of M3 receptors in the airways is relaxation of smooth muscles. Inhalation method for introduction of tiotropium has a selective effect, while in therapeutic doses does not cause systemic anticholinergic side effects. Bronchodilatory effect is dose-dependent and persists for at least 24 hours, due to slow dissociation from the M3 receptor. Release of the M2 receptor is faster than from M3. High affinity to the receptor and slow dissociation determine the severity and duration bronchodilatory effect in patients with COPD. Significantly improves lung function (FVC) at 30 min after a single dose increases the morning and evening peak expiratory flow rate. Pharmacodynamic equilibrium is reached within 1 week and pronounced bronchodilatory effect was observed for 3 days.
Indications Spiriva Inhaler:
COPD (including chronic bronchitis and emphysema).
Contra Spiriva Inhaler:
Hypersensitivity, pregnancy (I term), the age of 18 let.C caution. Angle-closure glaucoma, prostatic hyperplasia, bladder neck obstruction.
Side effects of Spiriva Inhaler:
From the digestive system: dry mouth (usually disappears in the course of treatment), constipation. With the respiratory system: cough and irritation of the oropharynx, paradoxical bronchospasm. From the CVS: tachycardia. With the genitourinary system: difficulty urinating, urinary retention (in men with predisposing factors). Allergic reaction: angioedema. From the senses: blurred vision, a sharp rise in intraocular davleniya.Peredozirovka. Symptoms: increased anticholinergic reactions (dry mouth, paresis of accommodation, and tachycardia. Treatment: symptomatic.
Dosing and Administration Spiriva Inhaler:
Inhalation using a special instrument, take 1 capsule a day at the same time. Older patients with renal / hepatic failure correction dosing regimen is not required.
Special instructions:
The drug should not be used for relief of bronchospasm. Inhalation of the drug can lead to bronchospasm. During treatment, patients with chronic renal failure should be closely monitored. Patients should be instructed on the rules of using the inhaler. Avoid getting powder into his eyes. You should not use more than 1 time per day.
Interaction:
Avoid concomitant use with other anticholinergic drugs. Tiotropiuma possible to use in combination with other drugs commonly used to treat COPD: sympathomimetics, methylxanthines, oral and inhaled corticosteroids.
